| XLS Download |
|
Total revenues, sales, operating result (EBIT), and R&D costs broken down by division (€ million) | |||||||||||||||||
|
|
|
|
|
|
| ||||||||||||
|
|
|
|
|
|
| ||||||||||||
|
|
Merck Serono |
Consumer Health |
Performance Materials |
Merck Millipore |
Group** | ||||||||||||
|
|
|
|
|
|
| ||||||||||||
| |||||||||||||||||
|
2011* |
|
|
|
|
| ||||||||||||
|
5,920.0 |
496.2 |
1,467.4 |
2,392.8 |
10,276.4 | |||||||||||||
|
Sales |
5,564.4 |
494.2 |
1,464.7 |
2,382.6 |
9,905.9 | ||||||||||||
|
Total operating result (EBIT) |
342.2 |
46.9 |
691.0 |
235.4 |
1,132.1 | ||||||||||||
|
Research and development costs |
1,224.5 |
22.8 |
132.8 |
133.4 |
1,514.0 | ||||||||||||
|
|
|
|
|
|
| ||||||||||||
|
2012 |
|
|
|
|
| ||||||||||||
|
Total revenues |
6,405.2 |
475.2 |
1,675.6 |
2,619.9 |
11,172.9 | ||||||||||||
|
Sales |
5,995.8 |
472.6 |
1,674.2 |
2,598.2 |
10,740.8 | ||||||||||||
|
Total operating result (EBIT) |
508.3 |
4.3 |
598.5 |
233.2 |
963.6 | ||||||||||||
|
Research and development costs |
1,187.3 |
19.4 |
137.4 |
166.1 |
1,511.3 | ||||||||||||
2012 was a highly successful year for Merck, shaped by significant changes. Total Merck Group sales rose by 8.7% to € 11,173 million due to organic growth of 4.8%, growth from currency effects of 3.6% and a 0.3% increase resulting from acquisition effects (see Annual Report 2012, Financial Position and Results of Operations ).
In 2012, the Merck Group reported a 14.9% decline in the operating result (EBIT ) to € 964 million, while the operating result excluding depreciation and amortization (EBITDA ) was down 13.6% to € 2,360 million, primarily due to the one-time restructuring costs (see Annual Report 2012, Financial Position and Results of Operations ).
At € 1,511 million, R&D spending remained roughly at the 2011 level (see Annual Report 2012, Financial Position and Results of Operations ).
search hit 02
